ALBRIOZA Commercial Launch

Canada ALBRIOZA™ Commercial Launch Underway in Canada 1st First Regulatory Approval for Amylyx Worldwide ALBRIOZA commercial launch in Canada underway; moving with urgency to make ALBRIOZA available to Canadians living with ALS. Approximately 1,000 people die from ALS in Canada every year, with a similar number of diagnoses annually. New Treatment Option Available for Canadians ALBRIOZA is only the third product candidate to be approved for the treatment of ALS in Canada in the past 30 years. Unmet need remains high, with ~3,000 Canadians living with ALS. Navigating Complex Reimbursement System ~40% of Canadians are covered by private insurance. Negotiated agreements with all of the largest private insurers to cover ALBRIOZA, represents ~80% of privately insured population ~60% of Canadians rely on public insurance. By the end of 2023, Amylyx expects to finalize and sign product listing agreements with the majority of federal, provincial, and territorial public drug plans. Experienced Team Driving Dalbrioza sodium phenylbutyrate and ursodoxicoltaurine powder for suspension TM Successful Launch in Canada Staffed by a team with considerable experience with new therapy launches in Canada Chris Aiello Head of Canada and General Manager Julie Girodat Head of Patient Services & Distribution sanofi Bioverativ Biogen AMGEN Bristol Myers Squibb™ Celgene Tracey Jason, PhD abbvie Celgene Pfizer Head of Medical Affairs Jason Lee Head of Market Access Blaine MacNeil Head of Sales, Marketing and Commercial Operations BAYER Biogen Lilly BAYER sanofi AMYLYX 15

View entire presentation